This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Protalix BioTherapeutics’s 8K filing here.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
See Also
- Five stocks we like better than Protalix BioTherapeutics
- Do ETFs Pay Dividends? What You Need to Know
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The Next 2 AI Winners Have Triple-Digit Upside Potential
